Concepts (211)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 7 | 2024 | 270 | 1.630 |
Why?
|
| Carcinoma, Renal Cell | 7 | 2017 | 75 | 1.080 |
Why?
|
| Kidney Neoplasms | 7 | 2017 | 98 | 1.050 |
Why?
|
| Urologic Neoplasms | 3 | 2021 | 13 | 0.940 |
Why?
|
| Cystectomy | 4 | 2017 | 103 | 0.920 |
Why?
|
| Urologists | 2 | 2019 | 5 | 0.760 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 2 | 2020 | 11 | 0.750 |
Why?
|
| Neoplastic Syndromes, Hereditary | 2 | 2017 | 5 | 0.660 |
Why?
|
| Biopsy | 2 | 2017 | 201 | 0.630 |
Why?
|
| Urinary Bladder Neoplasms | 5 | 2017 | 159 | 0.600 |
Why?
|
| Physicians, Primary Care | 1 | 2017 | 9 | 0.580 |
Why?
|
| Androgen Antagonists | 1 | 2017 | 17 | 0.580 |
Why?
|
| Insurance Coverage | 1 | 2017 | 31 | 0.580 |
Why?
|
| Insurance, Health | 1 | 2017 | 51 | 0.580 |
Why?
|
| Penile Neoplasms | 1 | 2016 | 12 | 0.520 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2015 | 5 | 0.520 |
Why?
|
| Neoplasm Staging | 11 | 2017 | 462 | 0.510 |
Why?
|
| Male | 25 | 2024 | 13022 | 0.500 |
Why?
|
| Ultrasound, High-Intensity Focused, Transrectal | 1 | 2015 | 4 | 0.500 |
Why?
|
| Papillomavirus Vaccines | 1 | 2016 | 53 | 0.490 |
Why?
|
| Humans | 37 | 2024 | 27119 | 0.470 |
Why?
|
| Algorithms | 1 | 2017 | 422 | 0.470 |
Why?
|
| Thymus Neoplasms | 4 | 2014 | 8 | 0.460 |
Why?
|
| Papillomavirus Infections | 1 | 2016 | 137 | 0.460 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 155 | 0.460 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 285 | 0.420 |
Why?
|
| Prostate-Specific Antigen | 2 | 2024 | 51 | 0.350 |
Why?
|
| Urologic Diseases | 1 | 2010 | 6 | 0.350 |
Why?
|
| Radiation Dosage | 1 | 2010 | 53 | 0.340 |
Why?
|
| Neoplasms, Glandular and Epithelial | 3 | 2014 | 67 | 0.330 |
Why?
|
| Aged | 13 | 2024 | 5222 | 0.320 |
Why?
|
| Prostatectomy | 1 | 2009 | 83 | 0.320 |
Why?
|
| Urology | 2 | 2019 | 27 | 0.310 |
Why?
|
| Middle Aged | 14 | 2024 | 6900 | 0.300 |
Why?
|
| Germ-Line Mutation | 3 | 2016 | 29 | 0.280 |
Why?
|
| Female | 18 | 2024 | 14635 | 0.270 |
Why?
|
| Early Detection of Cancer | 2 | 2024 | 122 | 0.250 |
Why?
|
| Multidrug Resistance-Associated Proteins | 2 | 2003 | 13 | 0.230 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2016 | 54 | 0.230 |
Why?
|
| Retrospective Studies | 9 | 2017 | 2454 | 0.230 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2016 | 655 | 0.220 |
Why?
|
| Smartphone | 1 | 2024 | 58 | 0.220 |
Why?
|
| Mobile Applications | 1 | 2024 | 58 | 0.220 |
Why?
|
| Nephrectomy | 3 | 2014 | 48 | 0.220 |
Why?
|
| Aged, 80 and over | 6 | 2024 | 1940 | 0.210 |
Why?
|
| Gram-Negative Bacteria | 1 | 2003 | 58 | 0.210 |
Why?
|
| Adult | 8 | 2024 | 7492 | 0.200 |
Why?
|
| Young Adult | 4 | 2017 | 2626 | 0.190 |
Why?
|
| Risk Factors | 5 | 2016 | 2030 | 0.190 |
Why?
|
| Oncologists | 1 | 2021 | 15 | 0.180 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2024 | 282 | 0.180 |
Why?
|
| Minority Health | 1 | 2019 | 4 | 0.170 |
Why?
|
| Rural Health Services | 1 | 2019 | 22 | 0.170 |
Why?
|
| Referral and Consultation | 2 | 2019 | 94 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 497 | 0.160 |
Why?
|
| Disease Progression | 2 | 2017 | 458 | 0.160 |
Why?
|
| Patient Selection | 1 | 2019 | 143 | 0.160 |
Why?
|
| Genetic Testing | 2 | 2017 | 64 | 0.160 |
Why?
|
| Prognosis | 7 | 2015 | 763 | 0.160 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 299 | 0.150 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 139 | 0.150 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 205 | 0.150 |
Why?
|
| Neoplasm Metastasis | 2 | 2016 | 150 | 0.150 |
Why?
|
| Androstane-3,17-diol | 1 | 2017 | 9 | 0.150 |
Why?
|
| Anabolic Agents | 1 | 2017 | 12 | 0.150 |
Why?
|
| Aldo-Keto Reductase Family 1 Member C3 | 1 | 2017 | 21 | 0.150 |
Why?
|
| Receptors, GABA-A | 1 | 2017 | 18 | 0.150 |
Why?
|
| Delayed Diagnosis | 1 | 2017 | 18 | 0.150 |
Why?
|
| Research Report | 1 | 2017 | 22 | 0.140 |
Why?
|
| Mutation | 3 | 2017 | 818 | 0.140 |
Why?
|
| Checklist | 1 | 2017 | 21 | 0.140 |
Why?
|
| Leiomyomatosis | 1 | 2017 | 2 | 0.140 |
Why?
|
| Leiomyoma | 1 | 2017 | 9 | 0.140 |
Why?
|
| Child | 2 | 2015 | 2160 | 0.140 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2016 | 537 | 0.130 |
Why?
|
| Quality Improvement | 1 | 2017 | 113 | 0.130 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2017 | 70 | 0.130 |
Why?
|
| Uterine Neoplasms | 1 | 2017 | 70 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2016 | 16 | 0.130 |
Why?
|
| Genetic Counseling | 1 | 2015 | 14 | 0.130 |
Why?
|
| Ultrasonic Therapy | 1 | 2015 | 4 | 0.130 |
Why?
|
| Body Temperature | 1 | 2015 | 30 | 0.130 |
Why?
|
| Papillomaviridae | 1 | 2016 | 85 | 0.130 |
Why?
|
| Antineoplastic Agents | 2 | 2024 | 658 | 0.130 |
Why?
|
| Registries | 1 | 2017 | 383 | 0.120 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 118 | 0.120 |
Why?
|
| Cisplatin | 1 | 2016 | 175 | 0.120 |
Why?
|
| Vaccination | 1 | 2016 | 175 | 0.120 |
Why?
|
| Internship and Residency | 1 | 2017 | 228 | 0.110 |
Why?
|
| Colonic Neoplasms | 1 | 2016 | 116 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 58 | 0.110 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2014 | 26 | 0.110 |
Why?
|
| Oklahoma | 1 | 2017 | 978 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2014 | 49 | 0.110 |
Why?
|
| Dyskeratosis Congenita | 1 | 2013 | 1 | 0.110 |
Why?
|
| Microcephaly | 1 | 2013 | 8 | 0.110 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2013 | 6 | 0.110 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2003 | 23 | 0.110 |
Why?
|
| Blood Loss, Surgical | 1 | 2013 | 52 | 0.110 |
Why?
|
| Fetal Growth Retardation | 1 | 2013 | 30 | 0.110 |
Why?
|
| Intellectual Disability | 1 | 2013 | 16 | 0.110 |
Why?
|
| Treatment Outcome | 4 | 2016 | 2283 | 0.110 |
Why?
|
| Cohort Studies | 4 | 2017 | 863 | 0.100 |
Why?
|
| DNA Helicases | 1 | 2013 | 51 | 0.100 |
Why?
|
| ABO Blood-Group System | 1 | 2012 | 7 | 0.100 |
Why?
|
| Infant | 1 | 2015 | 966 | 0.100 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 245 | 0.100 |
Why?
|
| Child, Preschool | 1 | 2015 | 1100 | 0.100 |
Why?
|
| Kidney Tubules, Collecting | 1 | 2011 | 4 | 0.090 |
Why?
|
| Muscle, Skeletal | 1 | 2015 | 622 | 0.090 |
Why?
|
| Malnutrition | 1 | 2011 | 30 | 0.090 |
Why?
|
| Adolescent | 2 | 2015 | 2988 | 0.090 |
Why?
|
| Nutritional Status | 1 | 2011 | 75 | 0.090 |
Why?
|
| Survival Analysis | 3 | 2016 | 278 | 0.090 |
Why?
|
| Survival Rate | 4 | 2012 | 411 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 340 | 0.080 |
Why?
|
| Renal Insufficiency | 1 | 2009 | 20 | 0.080 |
Why?
|
| Proportional Hazards Models | 3 | 2014 | 217 | 0.070 |
Why?
|
| Ovarian Neoplasms | 1 | 2014 | 566 | 0.070 |
Why?
|
| Kidney | 1 | 2009 | 276 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 445 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 466 | 0.070 |
Why?
|
| United States | 3 | 2019 | 2060 | 0.070 |
Why?
|
| Time Factors | 3 | 2017 | 1570 | 0.070 |
Why?
|
| Jews | 2 | 2016 | 7 | 0.060 |
Why?
|
| Genome, Human | 2 | 2016 | 67 | 0.060 |
Why?
|
| Biological Transport, Active | 1 | 2003 | 17 | 0.060 |
Why?
|
| Tennessee | 2 | 2014 | 26 | 0.050 |
Why?
|
| Lipoproteins | 1 | 2003 | 95 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2024 | 397 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2024 | 589 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 364 | 0.050 |
Why?
|
| Escherichia coli Proteins | 1 | 2003 | 113 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2003 | 236 | 0.050 |
Why?
|
| Telemedicine | 1 | 2024 | 164 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 189 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2015 | 595 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2003 | 330 | 0.040 |
Why?
|
| Animals | 2 | 2024 | 10080 | 0.040 |
Why?
|
| Eligibility Determination | 1 | 2019 | 5 | 0.040 |
Why?
|
| Sample Size | 1 | 2019 | 17 | 0.040 |
Why?
|
| Informed Consent | 1 | 2019 | 23 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 234 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2013 | 1219 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2017 | 95 | 0.040 |
Why?
|
| American Cancer Society | 1 | 2017 | 4 | 0.040 |
Why?
|
| Fumarate Hydratase | 1 | 2017 | 4 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 310 | 0.030 |
Why?
|
| Medicaid | 1 | 2017 | 52 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2017 | 89 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2017 | 209 | 0.030 |
Why?
|
| Robotic Surgical Procedures | 1 | 2017 | 43 | 0.030 |
Why?
|
| Pharmacogenomic Variants | 1 | 2016 | 1 | 0.030 |
Why?
|
| Thermometers | 1 | 2015 | 1 | 0.030 |
Why?
|
| Heating | 1 | 2015 | 6 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2016 | 107 | 0.030 |
Why?
|
| Neoplasms | 1 | 2024 | 766 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 251 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 48 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2016 | 69 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 230 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2015 | 132 | 0.030 |
Why?
|
| Haplotypes | 1 | 2016 | 279 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2015 | 18 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 104 | 0.030 |
Why?
|
| Equipment Design | 1 | 2015 | 211 | 0.030 |
Why?
|
| Mice | 1 | 2024 | 4473 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2016 | 122 | 0.030 |
Why?
|
| Leg | 1 | 2015 | 131 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 226 | 0.030 |
Why?
|
| Genotype | 1 | 2016 | 443 | 0.030 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 1 | 2014 | 2 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2017 | 774 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 119 | 0.030 |
Why?
|
| International Agencies | 1 | 2013 | 6 | 0.030 |
Why?
|
| Genes, Recessive | 1 | 2013 | 21 | 0.030 |
Why?
|
| Ligation | 1 | 2013 | 39 | 0.030 |
Why?
|
| Sutures | 1 | 2013 | 15 | 0.030 |
Why?
|
| Homozygote | 1 | 2013 | 36 | 0.030 |
Why?
|
| Program Development | 1 | 2013 | 75 | 0.030 |
Why?
|
| Telomere | 1 | 2013 | 32 | 0.030 |
Why?
|
| Telomerase | 1 | 2013 | 37 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 141 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2013 | 73 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 1037 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2017 | 1379 | 0.020 |
Why?
|
| Phenotype | 1 | 2013 | 667 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2011 | 15 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2011 | 35 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 180 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 225 | 0.020 |
Why?
|
| Weight Loss | 1 | 2011 | 72 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 988 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2011 | 389 | 0.020 |
Why?
|
| Biomarkers | 1 | 2011 | 738 | 0.020 |
Why?
|
| Membrane Fusion | 1 | 2003 | 7 | 0.010 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2003 | 35 | 0.010 |
Why?
|
| Spectrophotometry | 1 | 2003 | 34 | 0.010 |
Why?
|
| Alanine | 1 | 2003 | 40 | 0.010 |
Why?
|
| Cysteine | 1 | 2003 | 68 | 0.010 |
Why?
|
| Biological Transport | 1 | 2003 | 112 | 0.010 |
Why?
|
| Plasmids | 1 | 2003 | 122 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2003 | 88 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2003 | 262 | 0.010 |
Why?
|
| Membrane Transport Proteins | 1 | 2003 | 66 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 165 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2003 | 253 | 0.010 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2003 | 94 | 0.010 |
Why?
|
| Temperature | 1 | 2003 | 207 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2003 | 246 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2003 | 467 | 0.010 |
Why?
|